Over the years, Super Bowl commercials have become just as iconic as the yearly football game itself thanks to the likes of ...

Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related conditions. The Patels added, "With the addition of two denosumab ...

With a slower economy and higher unemployment, construction took a hit in 2025. Experts and research firms forecast a year of stabilization and recovery for commercial real estate in 2026. Here's what ...

Nike released a new Caitlin Clark commercial on Christmas Day, ahead of her 2026 CC Signature collection launch. Clark, a former Iowa women's basketball star, is asked throughout the commercial if she ...

Caitlin Clark signed with Nike in April of 2024, shortly after being drafted No.1 overall by the Indiana Fever. Kevin C. Cox / Getty Images Wear Caitlin Clark’s upcoming shoes and you can make it from ...

Commercial real estate has had a rough go after gaining momentum coming out of the pandemic. October was the first month of negative year-over-year transaction volume growth in the sector in nearly ...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and ...

Perkins Coie - New York - Real Property - Am Law 100: Top 50 - - New York Supreme Court, Kings County - Index not Assigned - Wilmington Trust, National Association, AS Trustee For The Benefit Of The ...

Credit: Fresenius Kabi. Conexxence and Bomyntra were approved by the FDA in March 2025. The interchangeability designation allows the biosimilars to be substituted for the reference product at the ...

The FDA has approved two new drugs that are biosimilars to denosumab, adding to the ever-expanding field of less expensive options of the popular anti-osteoporosis and cancer-related bone loss drug; ...

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...